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Abstract  
Metabotropic glutamate (mGlu) receptors are G protein-coupled receptors expressed 
primarily on neurons and glial cells modulating the effects of glutamatergic 
neurotransmission. The pharmacological manipulation of these receptors has been 
postulated to be valuable in the management of some neurological disorders. 
Accordingly, the targeting of mGlu5 receptors as a therapeutic approach for Parkinson’s 
disease (PD) has been proposed, especially to manage the adverse symptoms associated 
to chronic treatment with classical PD drugs. Thus, the specific pharmacological 
blocking of mGlu5 receptors constitutes one of the most attractive non-dopaminergic-
based strategies for PD management in general and for the L-DOPA-induced diskynesia 
(LID) in particular. Overall, we provide here an update of the current state of the art of 
these mGlu5 receptor-based approaches that are under clinical study as agents devoted 
to alleviate PD symptoms. 
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INTRODUCTION  
The amino acid L-glutamate (Glu) is recognized as the major excitatory 
neurotransmitter in the mammalian central nervous system (CNS) [1, 2]. Interestingly, 
the glutamatyergic system, apart from participating in the fast synaptic transmission, is 
also involved in neuronal plasticity and higher cognitive brain functions. In addition, 
excessive Glu can promote neuronal dysfunction and degeneration (i.e. neurotoxicity or 
excitotoxicity), and it has therefore been implicated in the pathogenesis of several 
chronic CNS neurodegenerative disorders such as amyotrophic lateral sclerosis, 
multiple sclerosis, Parkinson's disease (PD) and Alzheimer's disease (AD) [3, 4].  
The glutamatergic system is highly sophisticated; a fact evidenced by the exceptional 
organization of the glutamate receptor subtypes, which include both ionotropic (iGlu) 
and metabotropic (mGlu) receptor families [5, 6]. There are three classes of iGlu 
receptors, namely N-methyl-D-aspartic acid (NMDA) receptor, α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor and kainate receptors [3]. iGlu 
receptors, localized on neuronal and non-neuronal cells, mediate CNS fast excitatory 
synaptic transmission and therefore are postulated to play a key role in a large plethora 
of processes within the brain, spinal cord, retina, and peripheral nervous system [5]. 
Focusing on mGlu receptors, they are G protein-coupled receptors [7], and on the basis 
of their sequence similarity and pharmacological profile, are classified into three groups 
(I,II,III) [6]. Group I includes mGlu1 and mGlu5 receptors, which have quisqualic acid 
as their most potent agonist, are coupled to Gq/G11, and after its activation lead to the 
activation of phospholipase C [6]. Five splice variants of mGlu1 receptor have been 
described (i.e. α, β1, β2, γ and δ) [8], all of them differing in the length of their C-
terminal tail, which is thought to play a key role in the subcellular targeting of the 
receptor [6, 9, 10]. Similarly, two splice variants for the mGlu5 receptor have been 
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described, namely the mGlu5a and mGlu5b receptors, which differ in that mGlu5b 
receptor has a 33-amino acid insert in the intracellular C-terminal domain [11]. 
However, no functional differences have been reported between these two variants, 
although it has been postulated that alternative mGlu5 receptor splicing may contribute 
to regulatory mechanisms for tissue- and context-specific expression of the mGlu5 
receptor gene [12]. Interestingly, mGlu5 receptors are highly expressed within the CNS, 
thus they have been found in cerebral cortex (i.e. granule cells), hippocampus (i.e. 
dentate gyrus and pyramidal neurons of the CA1-3 area), olfactory bulb, lateral septum, 
striatum, nucleus accumbens and inferior colliculus [13]. At the subcellular level, 
mGlu5 receptors have been mostly found in neuronal postsynaptic elements, showing a 
perisynaptic and extrasynaptic distribution [14]. Thus, activation of postsynaptic mGlu5 
receptors may regulate ion channels functioning and increase the excitability of several 
types of neurons [15]. In addition, putative presynaptic mGlu5 autoreceptors have also 
been found, for instance in mouse cortical nerve endings [16], to facilitate glutamate 
exocytosis. On the other hand, group I mGlu receptors have been shown to be 
specifically involved in corticostriatal synaptic plasticity [17]. For instance, activation 
of mGlu1 receptor is required for the induction of corticostriatal long-term depression 
(LTD) [18-20], a fact that is linked to the receptor’s ability to modulate intracellular 
calcium concentration [21]. Or, it has also been shown that both mGlu1 and mGlu5 
receptors mediate in corticostriatal long-term potentiation (LTP), since simultaneous 
blockade of both receptors abolishes this phenomenon [22].  
Overall, mGlu receptors play a key role in CNS functioning, thus when the 
glutamatergic system is deregulated, as it occurs in excitotoxic brain conditions 
associated to some neurodegenerative diseases, the pharmacological manipulation of 
these receptors (i.e. blockade of group I or activation of group II and III mGlu 
 5 
receptors) has been postulated to exert beneficial effects. Accordingly, in the recent 
years it has been considered the usefulness of mGlu5 receptor blockade as a non-
dopaminergic therapeutic approach of PD, specially to manage the adverse symtoms 
associated to prolonged dopaminergic-based therapy (i.e. dyskinesia and motor 
fluctuations). 
 
GLUTAMATERGIC NEUROTRANSMISSION AND PARKINSON’S DISEASE  
Parkinson’s disease (PD) is one of the most common neurological disorders and affects 
approximately to 1% of individuals over the age of 60. It consists of a progressive 
systemic neurodegenerative disorder, in which different brain areas are affected (i.e. 
locus coeruleus, nucleus basalis of Meynert, dorsal raphe nucleus and the dorsal motor 
nucleus of the vagus), but it is primarily associated with the loss of pigmented 
dopaminergic neurons located within the pars compacta of the substantia nigra (SNc) 
[23] (Fig. 1C). The initial symptoms of the pathology (pre-motor phase) are poorly 
specific (i.e. fatigue, depression, constipation, decreased sense of smell and sleep 
problem), but when the disease advances (motor phase) the associated features and 
clinical signs are very well-characterized, including resting tremor, rigidity, 
bradykinesia, and postural instability [24]. Finally, since PD is a neurodegenerative 
condition, neuronal death continues beyond the motor phase, and it can affect other 
brain regions, for instance cortical areas, thus patients may then show cognitive 
dysfunctions and dementia [25]. Unfortunately, when PD motor signs emerge (pre-
clinical phase) around 60-80% of dopaminergic neurons are lost, a fact that points out to 
the relevance of finding a biomarker of the pathology, especially for early stages of the 
disease when the motor signs are not apparent [26]. 
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Glutamatergic neurotransmission within the basal ganglia circuitry is driven by cortical 
projections to the striatum -caudate and putamen in humans-, the subthalamic nucleus 
(STN) and the SNc; by thalamic projections to the cortex; and by STN afferents to the 
internal globus pallidus (GPi) and the substantia nigra pars reticulata (SNr) (Fig. 1). 
Inhibitory outputs (GABAergic) to the thalamocortical motor circuit are directed from 
the GPi and the SNr, where it acts to suppress movement. Accordingly, within the basal 
ganglia two major pathways exist and are referred to as the direct and indirect pathways 
(Fig. 1A and B). Interestingly, these two pathways are classically clasified acording to 
the dopamine receptor content of the GABAergic striatal medium spiny neurons (MSN) 
[27, 28]. Thus, the direct pathway, which projects to the GPi/SNr (Fig. 1A), contains the 
neuropeptides dynorphin (DYN) and substance P (SP) and it express the dopamine D1 
receptor (D1R) (Fig. 2). On the other hand, the indirect pathway, which projects to the 
globus pallidus pars externa (GPe) (Fig. 1B), contains the neuropeptide enkephaline 
(ENK) and express the dopamine D2 receptor (D2R) (Fig. 2). Regarding the normal 
functioning (non-pathological) of these structures, dopaminergic neurons from the SNc 
release dopamine into the putamen, which activates the direct pathway and inhibits the 
indirect pathway, and this results in a net inhibition of the GPi/SNr. Overall, this 
potentiates thalamocortical activity, which facilitates movements (Fig. 2), cognitive and 
behavioural outputs. Conversely, in PD, because of the loss of dopaminergic neurons in 
the SNc, striatal dopamine is reduced and the inhibition of the GPi/SNr decreases (Fig. 
1C). As a consequence, an increment of the GABAergic activity coming from GPi and 
SNr, the output nuclei of the basal ganglia (Fig. 1C), is observed and ends in both a 
reduction of the excitability of thalamic neurons and an alteration of their firing pattern 
[29, 30]. On the other hand, the glutamatergic activity of the subthalamic projection 
neurons and the corticostriatal pathway is highly increased. Importantly, this last fact 
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has lead to some interventional PD therapies aimed to drastically reduce this increased 
glutamatergic activity of the STN, for instance surgical ablation and functional 
inactivation through deep brain stimulation [31, 32]. However, all surgical procedures 
have associated risks and surgery is not suitable for everyone (typically only for 
advanced PD refractory to pharmacotherapy). Therefore, common PD management is 
still mainly achieved by means of pharmacological treatments (i.e. L-DOPA), and given 
the tight interconnection between dopaminergic and glutamatergic neurotransmission 
established in the basal ganglia both in normal and in pathological conditions, the 
inclusion of other drugs (i.e. mGlu5 blockers) targeting these systems is now under 
study and it is precisely the focus of this review.  
mGlu5 receptors are expressed throughout the whole basal ganglia, thus they can be 
found in the striatum (caudate nucleus and putamen), the globus pallidus, the substantia 
nigra, and the subthalamic nucleus (Fig. 2) [33]. Therefore, mGlu5 receptors may fine-
tune the basal ganglia function by modulating virtually all synaptic contacts present in 
this group of interconnected subcortical nuclei. For instance, mGlu5 receptors modulate 
corticostriatal excitatory inputs to the basal ganglia, since they are located both in D1R- 
and D2R-containing striatal MSNs (Fig. 2), although because of this dichotomy in its 
striatal distribution it is difficult to predict the net effect of mGlu5 receptor 
activation/inhibition on the transmission of the direct and indirect pathways. In addition, 
mGlu5 receptors would modulate transmission through the direct (striatonigral) 
pathway because they are located in GPi and SNr neurons. Thus, it has been reported 
that receptor activation produced disinhibition of nigral output neurons by decreasing 
GABAergic inhibitory transmission [34]. Finally, mGlu5 receptors would also modulate 
transmission through the indirect pathway by its location at the striatopallidal, 
pallidosubthalamic and subthalamonigral synapses (Fig. 2) (for review see [33]). 
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Collectively, these studies point out to a scenario in which mGlu5 receptor targeting 
within the basal ganglia will take place at different sites of action according to 
receptor’s distribution, a fact that would potentially enhance the pharmacotherapy based 
on this type of receptors. Accordingly, it is feasible that the net effect of mGlu5 receptor 
antagonists on basal ganglia motor function results from the overall receptor targeting at 
several different sites including the striatum, STN, and SNr neurons [33].  
 
MOLECULAR ASPECTS OF STRIATAL mGlu5 RECEPTORS  
mGlu5 receptor interacting proteins 
mGlu5 receptors belong to class C of G protein-coupled receptors (GPCRs) [35] and are 
composed of a ligand-binding domain linked through a cysteine-rich domain (CRD) to a 
typical seven transmembrane domain common to all GPCRs, followed by a C-terminal 
intracellular tail which is variable in length (see above) [6]. Interestingly, apart from of 
the classical G-protein coupled signal cascades, mGlu5 receptors physically interact 
with a large variety of accessory proteins, which ensure the correct targeting and 
anchoring at synaptic specialization, thus  increasing the diversity of receptor coupled 
signal cascades [36]. Thus, apart from of interacting with cytoskeletal (i.e. α-actinin 
[37], and filamin-A [38]) and scaffold (i.e. CAL [39], Homer [40], NHERF-2 [41] and 
tamalin [42]) proteins, which impinge into the trafficking and anchoring of the receptor 
to specialized plasma membrane domains (i.e. synapses), mGlu5 receptors also interact 
with enzymes or proteins directly involved in intracellular signal pathways (i.e. CAIN 
[43], calmodulin [44], ephrin2B [45], NECAB2 [46], Norbin [47], optineurin [48], PKC 
[49], PP1γ [50] and Siah-1 [51]). In addition, since mGlu5 receptors are plasma 
membrane proteins they also have the ability to laterally interact with other plasma 
membrane proteins, including GPCRs and ion channels. Indeed, mGlu5 receptors are 
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able to form homo- and heteromers at the plasma membrane level [52, 53], and while 
receptor homodimers require the formation of a covalent disulphide bridge between the 
extracellular N-terminal domain [53] the heteromerization might involve the 
transmembrane domains [54]. mGlu5 receptors may also heteromerize with other 
GPCRs belonging to a different receptor family (i.e. family A) such as the µ-opioid 
receptor [55], the adenosine A2A receptor (A2AR) [56] and the D2R [57].  
 
Striatal mGlu5 receptor containing oligomers  
As described early, the striatum, the input nucleus of the basal ganglia [58], receives 
dopaminergic and glutamatergic afferents that converge in the dendritic spines of MSNs 
(for review see [59]) (Fig. 3). Thus, glutamatergic synapses are located at the head, 
while the dopaminergic afferents are usually located at the neck, of dendritic spines 
(Fig. 3). As a consequence, dopamine plays a major modulatory role into the excitatory 
effects of glutamate in the dendritic spines [60]. Importantly, in addition to dopamine 
and glutamate, the neuromodulator adenosine also plays a key role in the function of 
striatal GABAergic efferent neurons [61]. Interestingly, adenosine A2A receptors 
(A2ARs) are highly concentrated in the striatum, where by means of ultrastructural 
studies have been located at the dendritic spines of indirect pathway MSNs (i.e. the 
striatopallidal neurons), especially in the vicinity of glutamatergic synapses [62, 63], 
and thus presenting a very similar localization to that described for mGlu5 receptors [14] 
(Fig. 3). In fact, it has been reported that A2ARs functionally interact with mGlu5 
receptors to modulate several downstream mGlu5 receptor-mediated effects (for review 
see [64]). Therefore, A2AR and mGlu5 receptor agonists and A2AR and mGlu5 receptor 
antagonists have been shown to produce synergistic effects at the behavioral level [65-
67]. Thus, these functional and morphological frameworks, together with the fact that it 
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is well-established that mGlu5 receptors are able to form homo- and heteromers at the 
plasma membrane level [52, 53], supports the possible existence of a physical 
interaction between striatal A2ARs and mGlu5 receptors. Indeed, a A2AR-mGlu5 receptor 
interaction has been described both in heterologous expression systems and in native 
tissue, namely the striatum [56]. Interestingly, at this level the co-stimulation of both 
receptors leads to a synergistic effect on downstream signalling that may allow 
overriding the inhibitory tone imposed by endogenous dopamine acting at the D2R [56]. 
Accordingly, it has also been considered the existence of oligomeric complexes that 
simultaneously contain adenosine, dopamine and glutamate receptors (e.g 
A2AR/D2R/mGlu5 receptor) [57, 68] (Fig. 3). This oligomer would be located adjacent 
to the glutamatergic synapse of the dendritic spine of the ENK MSN, where the cross-
talk within the receptor heteromers might help in theory to achieve a much more 
elaborated tuning in the regulation of both presynaptic and postsynaptic neuronal 
responses in the striatal local circuitry and to a proper performance of the striatal 
function [69-71] (Fig. 3). Overall, since these protein-protein interactions may play a 
key role in the mGlu5 receptor-mediated control of glutamatergic neurotransmission 
they might be potentially involved in the pathophysiology of neurodegenerative and 
neuropsychiatric disorders, including addiction, depression, epilepsy, schizophrenia, 
Alzheimer´s, Huntington´s and Parkinson’s disease [72], thus leading to consider 
oligomerization processes as new targets for the treatment of these pathologies. 
 
The rationale of blocking mGlu5 receptor in PD 
As it has been previously commented, the management of PD still mainly consists of a 
pharmacological approach. Thus, the majority of these drug-based treatments look for 
restoring striatal dopamine signalling, in order to diminish the intensity of the occurring 
 11 
motor and non-motor symptoms. The most effective therapy for the management of this 
disease is therefore based on the use of drugs that mimic dopamine, initially the 
precursor L-DOPA (L-3,4-dihydroxyphenylalanine) [73] and later on other 
dopaminergic agents, which act to compensate for the loss of this neurotransmitter [74]. 
Interestingly, although L-DOPA and D2R agonists have been proved very efficacious in 
the management of PD symptoms, chronic treatment with these agents can result in a 
loss of efficacy and the appearance of motor (e.g. dyskinesia) and non-motor 
complications (e.g. psychosis and impulse-control disorders) [75]. Thus, as the disease 
progresses, smaller amount of dopamine neurons are available to store and release L-
DOPA-derived dopamine, and the patient's clinical status begins to fluctuate more and 
more, closely in accordance with the levels of L-DOPA in plasma. In addition, 
fluctuating L-DOPA-derived dopamine concentrations, in association with the disease 
progression, may be responsible for the development of motor fluctuations and 
dyskinesia (e.g. L-DOPA-induced diskynesia or LID). 
It has been largely demonstrated that the pharmacological effects of mGlu5 receptor 
agonists and antagonists produced in some behavioural animal models parallels well 
with the effects observed after the treatment with A2AR agonists and antagonists, 
respectively, specifically during the selective modulation of the D2R-mediated 
responses. Thus, A2AR and mGlu5 receptor would synergize in the control of D2R-
mediated function, and it has been then postulated that this interaction would be 
instrumented by the feasible A2AR/D2R/mGlu5 receptor oligomer located at the MSN 
(Fig. 3). In such way, upon A2AR and mGlu5 receptor co-stimulation, D2R-mediated 
transmission has been shown to be blocked [56, 65, 76], thus suggesting that the former 
oligomer (i.e. A2AR/D2R/mGlu5 receptor) may play a key role on striatal neuronal 
function and dysfunction [56, 77-80]. Accordingly, it is well-accepted that a balanced 
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glutamatergic, dopaminergic and adenosinergic neurotransmission is needed for proper 
striatal functioning, and that the A2AR/D2R/mGlu5 receptor oligomer operates as a MSN 
integrative receptorial unit with an extraordinary degree of computation in sensing 
glutamate, dopamine and adenosine concentrations at the striatum (Fig. 3) [69, 70]. 
Overall, all this data provide a rationale for using A2AR and mGlu5 receptor antagonists 
in PD [81, 82].  Furthermore, these non-dopaminergic-based PD therapies may also 
offer some advantages over dopamine medications, for instance by reducing side effects 
[83]. 
From the different promising PD treatments based on the indirect modulation of 
dopaminergic neurotransmission (for review see [83]), the use of mGlu5 receptor 
blockers has recently received considerable attention by the scientific community. Thus, 
preclinical data suggested that mGlu5 receptor blockers might not only be useful in PD 
treatment by potentiating the benefit of dopamine-based therapies but also by allowing 
drug dose lowering and by preventing LID development, which has precisely been 
associated to an increase of striatal glutamatergic neurotransmission [84]. Indeed, the 
use of PD animal models in preclinical studies has proved to be valuable experimental 
tools to assess the efficacy of mGlu5 receptor-based drugs on both reversing motor 
symptoms and slowing the associated progressive neurodegeneration. Genetic PD 
animal models based on specific mutations of genes observed in PD familial cases (e.g. 
alterations in parkin, α-synuclein, leucine-rich repeat kinase 2 (LRRK2), phosphatase 
and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) and Parkinson disease -
autosomal recessive, early onset- 7 (PARK7)) [85] have been shown to be useful for the 
study of the pathogenesis of familial PD, although since these animal models do not 
recreate some characteristics of the human disease (e.g. severe motor deficits, lack of 
dopaminergic neurons degeneration, etc.) they are experimentally restricted to disease 
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associated molecular and cellular studies and often inadequate to pharmacotherapy 
studies [86]. Accordingly, the preclinical evaluation of mGlu5 receptor-based drugs 
have largely relied on pharmacological and toxin-based animal models of PD because 
these last models often replicate specific pathogenic events and behavioral outcomes of 
PD. The neurotoxic PD animal models based on systemic or intracerebral 
administration of compounds that produce both reversible (i.e. haloperidol and 
reserpine) and irreversible (i.e. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 
6-hydroxydopamine (6-OHDA), paraquat and rotenone) parkinsonian effects have been 
effectively used in PD pharmacotherapy studies. Indeed, since the irreversible toxin-
based models of PD recapitulate the morphological aspects of the disease (i.e. 
dopaminergic system degeneration), and also produce a PD-related pathology and 
symptomatology, they constitute golden standards models in the study of the disease-
modifying potential of the mGlu5 receptor-based drugs. 
The 6-OHDA is a classic and widespread toxin-based animal model of PD [87] that has 
been successfully used in the study of the function of the mGlu5 receptor in PD. Partial 
bilateral 6-OHDA lesions cause akinetic deficits in reaction time tasks, thus recreating a 
parkinsonian effect of the earlier stages of the disease. Interestingly, it was 
demonstrated that the chronic instead the acute treatment with 2-methyl-6-
(phenylethynyl)-pyridine (MPEP), a mGlu5 receptor antagonist, reversed these akinetic 
deficits [88, 89], therefore suggesting that MPEP treatment might alleviate PD-
associated motor executive deficits in an operant task. Also, the effects of MPEP on 
parkinsonian cognitive deficits has been studied and thus demonstrated that MPEP, 
either acutely or subchronically, antagonized the visuo-spatial discrimination deficit 
induced by bilateral 6-OHDA lesion of the striatum [90]. Moreover, in partially 
lesioned rats chronic systemic MPEP treatment was shown to be neuroprotective and to 
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reverse the abnormal firing activity of dopaminergic neurons [91]. Interestingly, in 
addition to the MPEP-mediated cognitive and behavioural effects, the same treatment 
also increased contralateral turning induced by L-DOPA in mice bearing unilateral 6-
OHDA lesion [90], thus confirming the therapeutic potential of mGlu5 receptor 
blockade on motor symptoms produced by reduced striatal dopaminergic transmission 
(for review see [92]). On the other hand, the MPTP animal model of PD, mainly used in 
nonhuman primates and mice (rats are resistant to MPTP) [93], also seed some light 
about the potential therapeutic usage of mGlu5 receptor antagonists in PD. Interestingly, 
an upregulation of mGlu5 receptors in the posterior putamen and pallidum of MPTP-
treated monkeys has been associated with LID development in this PD animal model 
[94], thus also supporting that mGlu5 receptor blockade might alleviate LIDs. Indeed, 
reduction of glutamatergic neurotransmission by selective mGlu5 receptor non-
competitive antagonists, either MPEP or 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine 
(MTEP), has been shown to improve locomotion and alleviate LID in PD animal 
models [95-97]. Needless to say, apart from the mGlu5 receptor blockers we revise here, 
other agents able to reduce glutamate neurotransmission might indeed become valued 
drugs to PD therapy. Thus, amantadine, an NMDA-receptor antagonist, has 
demonstrated efficacy in reducing LID both in animal models and PD patients, although 
its short-term efficacy, together with its neurological side effects, has precluded its 
clinical use [98, 99]. Overall, the antidyskinetic efficacy of selective mGlu5 receptor 
antagonists supports the hypothesis that abnormally increased glutamatergic 
neurotransmission is involved in LID and points to the mGlu5 receptor as a potential 
therapeutic target for the treatment of LID. Collectively, these preclinical studies 
supported the use of mGlu5 receptor antagonists as anti-parkinsonian drugs. 
 
 15 
CLINICAL EVALUATION OF mGlu5 RECEPTOR BLOCKERS IN PD 
In clinics, the therapeutic potential of mGlu5 receptors has been progressively explored, 
mainly for both peripheral and central nervous disorders ranging from psychiatric, 
neurological to neuromuscular illnesses [100]. Indeed, the usefulness of mGlu5 receptor 
blockers is actually being challenged not only in neurodegenerative disorders as PD but 
also in the treatment of addiction, pain, schizophrenia or anxiety disorders [101, 102]. 
Regarding the management of PD, these kind of compounds has been mainly proposed 
as adjuvant drugs to PD L-DOPA therapy, not only as a feasible option assisting the 
symptomatic PD treatment but mostly for the alleviation of LID [92]. Indeed, several 
negative allosteric modulators of mGlu5 receptors have been reported, with multiple 
compounds in preclinical or clinical development, such as fenobam (NP-2009), 
raseglurant (ADX10059), diplagurant (ADX48621), AFQ056 and others [103]. 
Nevertheless, it is also true that still few clinical trials assessing the efficacy of these 
compounds in human beings have been carried out (Table 1) or are ongoing (Table 2). 
From this plethora of compounds, it is worth mentioning the drug (3aR,4S,7aR)-
Octahydro-4-hydroxy-4-[(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methyl 
ester, named AFQ056 (Novartis Pharma AG, Basel, Switzerland), which is a potent 
selective negative allosteric modulator of the mGlu5 receptor, and that has been 
evaluated in animal models as well as in PD clinical trials, but also in other indications 
such as the fragile X syndrome [104, 105], nicotine addiction ([106] and gastro-
oesophageal reflux disease [107]. The clinical efficacy and safety of AFQ056 has been 
evaluated in a few number of double-blind, placebo-controlled randomised clinical trials 
involving patients with moderate to severe L-DOPA induced dyskinesias in PD 
(Novartis Clinical Trial Results Database: 
CAFQ056A2203;http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFi
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le.do?trialResult=3129;CAFQ056A2206,http://www.novctrd.com/ctrdWebApp/clinicalt
rialrepository/displayFile.do?trialResult=3402 [108]; 
CAFQ606A2208,http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFi
le.do?trialResult=4745  [109] and CAFQ056A2216, 
http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=
6483 [110]) (Table 1). Importantly, only the complete results of two of the clinical trials 
have been published [108], while the others just presented in international congresses 
[109, 110]. The primary objectives of these trials were to assess the antidyskinetic 
efficacy, as well as the safety and tolerability, of multiple AFQ056 doses on moderate 
to severe LID in PD patients. Interestingly, a low number (less than 300) of patients 
have been currently included in these clinical trials, whose main characteristics are 
shown in table 3. In brief, the mean age (SD) of the patients in these trials was 64.5 
(8.6) years old and approximately 53% were men. On the other hand, for the inclusion 
of these patients in the named clinical trials they had to have received L-DOPA for at 
least 3 years and were required to remain on stable L-DOPA therapy for the duration of 
these studies. Moreover, these patients were also required to have moderate to severe 
LID. Finally, it is also worth to mention that these studies were short in time (from two 
to twelve weeks) (Table 1).  
Regarding the dose of AFQ056 used, in two clinical trials it was steadily increased 
every 4 days from 25 mg to a maximum dose of 150 mg twice a day during a period of 
16 days (CAFQ056A2203 and CAFQ056A2206), and just in one of them patients were 
also down-titrated (50 mg twice a day) from day 17 to day 20 mg (CAFQ056A2206) 
[108]. Thus, in the studies carried out by Berg et al. [108] the mean dose received was 
of 103.57 and 111.70 mg twice a day in study 1 (CAFQ056A2203) and study 2 
(CAFQ056A2206), respectively. Conversely, Stocchi et al. compared different multiple 
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fixed-doses of AFQ056 (10, 25, 50, 75 and 100 mg twice a day; CAFQ606A2208) 
[109]. Finally, in the study performed by Kumar et al., AFQ056 was up-titrated during a 
two-week period treatment from 25 mg twice a day to 100 mg twice a day, when L-
DOPA was kept stable for a week and then it started a a three-week period in which the 
L-DOPA dose was increased. Finally, during the taper-off period both AFQ056 and L-
DOPA were gradually down titrated to the initial doses used during the run-in phase 
(CAFQ056A2216) [110].  
Concerning the primary outcome measured in the different clinical trials it consisted of 
assessing the anti-dyskinetic efficacy. Accordingly, different scales were used, such as 
Lang-Fanh Activities of Daily Living Dyskinesia Scale (LFADLDS) and modified 
Abnormal Involuntary Movement Scale (AIMS), as well as motor function using 
Unified Parkinson’s Disease Rating Scale (UPDRS) part III. Other secondary 
assessments of the anti-dyskinetic AFQ056 effects were done by means of other scales, 
such as UPDRS part IV (items 32-33) and Parkinson Disease Dyskinesia (PDYS-26). 
However, several methodological problems arise from using these PD scales to measure 
dyskinesia, which have been well described elsewhere [111]. For instance, as mentioned 
above, the short duration of these clinical trials, or importantly the lack of a fully 
validation of some scales (i.e. LFADLDS and the modified AIMS version), which may 
have limited the ability to detect changes in functional impairment among the study 
population. Therefore, although AFQ056 showed some antidyskinetic efficacy when 
measuring dyskinesia with the former scales, the clinical relevance of these results can 
be considered is vague and difficult to interpret (Table 4). Thus, no significant effects 
were seen on UPDRS-III in any study. Similarly, only in the Stocchi et al. study 
(CAFQ606A2208) [109] there was a dose-response relationship in the primary outcome 
(change from baseline at week 12 on the modified AIMS) with the 100 mg twice-a-day 
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dose (Table 5). And again, no significant changes were observed in any case on the 
secondary outcomes, such as Parkinson Disease Dyskinesia Scale (PDYS-26), Clinical 
Global Impression of Change (CGIC) and UPDRS-III. 
With respect to possible adverse effects of the studied drug, summing the total number 
of adverse events observed in the abovementioned four clinical trials, they were found 
in 128 patients out of 169 (75.7%) treated with AFQ056 and in 70 patients out of 100 
(70%) treated with placebo. The reported adverse events were typically mild to 
moderate in severity and included nervous system, gastrointestinal and psychiatric 
disorders (Table 6). Dizziness (15%) and dyskinesia (7%), followed by nausea (4%) and 
hallucinations (4%) were the most common adverse events in patients treated with 
AFQ056 (Table 6) while dyskinesia (18%) and nausea (8%) were the most frequent in 
patients treated with placebo. Importantly, twenty patients out of 169 patients treated 
with AFQ056 (11.8%) discontinued the experimental drug as a consequence of adverse 
events appearance. Concretely, in the two clinical trials carried out by Berg et al. 
(CAFQ056A2203 and CAFQ056A2206) [108], the most common severe adverse event 
was worsening of dyskinesia, which arose after stopping treatment. Thus, five severe 
adverse events were observed in the study 1 of Berg et al. (CAFQ056A2203), from 
which four occurred in the AFQ056 group and were considered serious (two patients 
experienced worsening of dyskinesia, one patient developed hyperkinesia, and one 
patient had two serious events, such as a fall and rhabdomyolisis). Similarly, in the 
study 2 of Berg et al. (CAFQ056A2206) there were four severe adverse events in the 
AFQ056 group and three in the placebo group, from which two in each group were 
considered serious adverse events. Noteworthy, and related to the results obtained in the 
study 1, two serious adverse events in AFQ056-treated patients were suspected to be 
related to the study medication. In particular, one patient developed psychosis, which 
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required discontinuation of treatment, while the other patient had dyskinesia worsening. 
In the Stocchi et al. study (CAFQ606A2208) [109], adverse events were reported by 
65.1% of the placebo group patients and by 75% of the medication study group of 
patients daily-treated with 100 mg of AFQ056. Importantly, adverse events requiring 
dosing modification or interruption increased progressively from 4.8% in the placebo 
group to 22.7% in the AFQ056 (200 mg/daily) group. Finally, serious adverse events 
were observed in 9.5% of the placebo group and in 11.4% of AFQ056 200 mg/daily-
treated patients. In such way, psychosis and psychotic disorders-related adverse events 
increased gradually from 1.6% in the placebo group to 22.7% in the AFQ056 (200 
mg/daily) group of patients.         
To finish with the AFQ056 characterization, it is needed to say that scarce information 
is available about AFQ056 pharmacokinetics. Thus, it has been shown that the steady 
state plasma concentration-time profiles of AFQ056 alone or when co-administered 
with L-DOPA/carbidopa are similar, thus indicating that the co-administration of a L-
DOPA/carbidopa combination has no relevant effects on AFQ056 pharmacokinetics 
[112]. On the other hand, the pharmacokinetics of AFQ056 has been shown to be 
altered in subjects with renal impairmen: the AUC (area under the plasma 
concentration-time curve) of AFQ506 is increased in patients with mild, moderate and 
severe renal impairment, compared with healthy control subjects (Novartis Clinical 
Trial Database: CAFQ056A2124, 
http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=
6624). Finally, no data is available assessing the pharmacokinetics of AFQ056 in 
subjects with hepatic impairment, although some studies are now ongoing.   
In summary, despite the promising results observed in preclinical studies, today there 
are few clinical trials, including a small number of PD patients, which have assessed the 
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efficacy and safety of mGlu5 receptor antagonists in humans. The preliminary results of 
these studies suggest some antidyskinetic efficacy in PD patients with LID, but the 
clinical relevance of the reported outcomes is uncertain and difficult to interpret due to 
the methodological problems associated with the measuring-scales used. On the other 
hand, adverse events (from mild to moderate in severity) associated with these drugs 
have been shown to be common (mainly gastrointestinal and neuropsychiatric 
disorders), and together with the fact that there is still lacking consistent 
pharmacokinetic data to establish the optimum drug-treatment, it is obvious that more 
research is needed to properly evaluate the therapeutic potential of this new group of 
drugs in the treatment of PD.      
  
CONCLUDING REMARKS 
The current pharmacological approach dealing with parkinsonian symptoms entirely 
relies on dopamine replacement therapy either with L-DOPA or with D2R agonists. 
However, long-term dopamine-based therapies promote the development of intolerable 
motor adverse effects like dyskinesia and motor fluctuations. As a consequence, a lot of 
effort has been focused on the search for new non-dopaminergic-based drugs to be 
incorporated into PD therapeutic arsenal. Indeed, mGlu5 receptor blockers constitute 
one of the most attractive non-dopaminergic classes of drugs for PD management in 
general and for the LID treatment in particular. Accordingly, these drugs would have 
antiparkinsonian effects by reducing the excitatory drive occurring in the enkephalin 
MSN of the overactive parkinsonian basal ganglia, a phenomenon that might be related 
to the physical interaction (oligomerization) between D2R and mGlu5 receptor in the 
MSN glutamatergic synapses. 
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ABBREVIATIONS 
AD =  Alzheimer`s disease 
A2AR = adenosine A2A receptor 
AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
CNS = central nervous system 
D1R = dopamine D1 receptor 
D2R = dopamine D2 receptor 
DYN = dynorphin 
ENK = enkephalin 
GABA = γ-aminobutyric acid 
Glu = L-glutamate 
GPCR = G protein-coupled receptor 
GPe = globus pallidus pars externa 
GPi = globus pallidus pars interna 
6-OHDA = 6-hydroxydopamine  
LC = locus coeruleus  
L-DOPA = L-3,4-dihydroxyphenylalanine 
LRRK2 = leucine-rich repeat kinase 2  
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iGlu = ionotropic glutamate  
LID = L-DOPA induced dyskinesias 
mGlu = metabotropic glutamate  
MPEP = 2-methyl-6-(phenylethynyl)pyridine  
MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MSN = GABAergic medium spiny neurons 
MTEP = 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine  
NMDA = N-methyl-D-aspartic acid  
PARK7 = Parkinson disease (autosomal recessive, early onset) 7  
PD = Parkinson’s disease 
PINK1 = PTEN-induced putative kinase 1 
PTEN  = phosphatase and tensin homolog  
SNc = substantia nigra pars compacta  
SNr = substantia nigra pars reticulata 
STN = subthalamic nucleus 
UPDRS = Unified Parkinson’s Disease Rating Scale 
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FIGURE LEGENDS 
Fig. 1. Scheme of the basal ganglia circuitry and its connection to the 
thalamocortical circuit in both normal and PD conditions. Dopaminergic neurons 
from the substantia nigra pars compacta (SNc, shown in black punctate) control the 
direct (A) and indirect (B) pathways within the basal ganglia via activation of D1R or 
D2R. Thus, the striatum, which in humans comprises the caudate and putamen, is linked 
to the complex formed by the substantia nigra pars reticulata (SNr) and the globus 
pallidus pars interna (GPi) via direct (striatonigral) and indirect (striatal-pallidal-
subthalamic-nigral) pathways. Accordingly, within the direct pathway (A) GABAergic 
projections (red arrows) inhibit the functioning of the basal ganglia output nuclei, the 
SNr-GPi complex. The SNr-GPi complex sends inhibitory projections (GABAergic; red 
arrows) to the thalamus, which in turn regulates excitatory output to the cortex 
(glutamatergic; green arrows). Dopaminergic neurons (blue arrows) from the substantia 
nigra pars compacta (SNc) project to medium spiny neurons (MSN) of the putamen 
which express D1R, thus stimulating transmission through the direct pathway. On the 
other hand, within the indirect pathway (B) GABAergic projections (red arrows) from 
the putamen project to the globus pallidus pars externa (GPe), which in turn project 
inhibitory projections (GABAergic; red arrows) to the GPi and subthalamic nucleus 
(STN). SNc dopaminergic neurons (blue arrows) project to putamen MSNs expressing 
D2R which thus reduce the activity of the indirect direct pathway. In addition, STN send 
excitatory (glutamatergic; green arrows) projections to the SNr-GPi complex, thus 
balancing the inhibitory tone mediated by the direct pathway and the level of inhibition 
of the thalamus, which modulates excitation of the motor areas of the cortex. In PD (C) 
there is a loss of SNc dopaminergic neurons which results in a reduction in the direct 
pathway-mediated inhibitory transmission and an increase in the indirect pathway-
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mediated inhibitory transmission, therefore resulting in an increased excitation of the 
output nuclei via the STN. Overall, this increase in the excitation of the SNr-GPi 
complex implies a concomitant increase of GABAergic tone at the thalamus which ends 
with a reduction of the excitation of cortical motor areas. Adapted from [92] and [113]. 
 
Fig. 2. Localization of dopamine, adenosine and metabotropic glutamate receptors 
within the basal ganglia circuitry. The dopamine, adenosine and metabotropic 
glutamate receptors with interest to PD therapy are depicted in a scheme showing the 
direct and indirect basal ganglia pathaways (see Fig. 1A and B). The co-distribution of 
D2R, A2AR and mGlu5 receptor within the same striatal neurons, namely the  
enkephalinergic medium spiny neuron, puts into significance the potential role of 
oligomers formed by these GPCRs and postulates the use of striatal mGlu5 receptors as 
therapeutic targets in PD. SNc: substantia nigra pars compacta; SNr: substantia nigra 
pars reticulata; GPi: globus pallidus pars interna; GPe: globus pallidus pars externa; 
STN: subthalamic nucleus; ENK: enkephalinergic neuron; DYN: dynorphinergic 
neuron. Adapted from [81]. 
 
Fig. 3. Schematic representation of a striatal GABAergic enkefalinergic neuron 
dendritic spine containing dopamine, adenosine and metabotropic glutamate 
receptors. The subcellular distribution of A2AR, D2R and mGlu5 receptor in rat striatum 
is shown (left panel). Electron micrograph showing immunoreactivity for A2AR, D2R 
and mGlu5 receptor in rat striatum as revealed using a triple-labeling post-embedding 
immunogold technique. Immunoparticles for A2AR (10 nm size, arrows), D2R (15 nm 
size, crossed arrows) and mGlu5 receptor (20 nm size, arrowheads) were detected along 
the extrasynaptic and perisynaptic plasma membrane of the same dendritic spine (s) 
establishing excitatory synaptic contact with axon terminals. Adapted from Ref. [57]. 
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Schematic representation of a striatal GABAergic enkefalinergic neuron dendritic spine 
(right panel). The A2AR/D2R/mGlu5 receptor oligomer shows a perisynaptic and 
extrasynaptic distribution within the dendritic spine of the enkephalin MSNs and 
controls the excitability of these neurons. Interestingly, under weak glutamatergic 
neurotransmission D2R activation, apart from inhibiting adenylyl-cyclase, it enhances 
phospholipase C (PLC) function, which activates protein-phosphatase2B (PP-2B or 
calcineurin), which in turns inactivates L-type voltage-dependent calcium channels (L-
type VDCCs). This is the main mechanism involved in the D2R-mediated suppression 
of activity in the striatopallidal neuron [114]. Accordingly, under weak glutamatergic 
neurotransmission D2R functioning predominates and a decrease in neuronal excitability 
is observed.  However, under conditions of strong glutamatergic neurotransmission, 
which is associated with adenosine release, there is a robust stimulation of both A2AR 
and mGlu5 receptor. The A2AR and mGlu5 receptor, through an oligomeric interaction, 
preclude D2R functioning and thus favours neuronal excitability. In green and red, 
stimulatory and inhibitory effects, respectively are shown. AMPAR: AMPA receptor. 
NMDAR: NMDA receptor. Adapted from [115]. 
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Table 1.  Randomised Clinical Trials with AFQ056 in Parkinson's Patients with L-DOPA Induced 
Dyskinesias (LID). 
Authors (year) 
study countries 
Phase and design 
clinical trial 
 
Patients 
Treatment 
(drugs, doses, length) 
 
Primary 
outcome 
Other 
outcomes 
Berg D et al. 
(2007-2008) 
Germany 
[108] 
 
●Phase II 
Multicenter, 
randomized, 
double blind, 
parallel-group, 
placebo-
controlled 
(randomisation 
ratio 1:1) 
31 subjects 
with 
moderate to 
severe LID 
 
●AFQ056 (n=15) 
dose-titration: 
Days 1-4: 25 mg bid 
Days 5-8: 50 mg bid 
Days 9-12: 100 mg 
bid 
Days 13-16: 150 mg 
bid 
Placebo (n=16) 
●LFADLDS 
Scale  
●UPDRS-III 
(motor 
function) 
●UPDRS -IV 
(motor 
complicationsi
tems 32-33) 
●mAIMS 
Berg D et al. 
(2009) 
Germany [108] 
●Phase II 
Multicenter, 
randomized, 
double blind, 
parallel-group, 
placebo-
controlled 
(randomisation 
ratio 1:1) 
28 subjects 
with severe 
LID 
●AFQ056 (n=14) 
dose-titration: 
Days 1-4: 25 mg bid 
Days 5-8: 50 mg bid 
Days 9-12: 100 mg 
bid 
Days 13-16: 150 mg 
bid 
 Placebo (n=14) 
●mAIMS 
(abnormal 
movements) 
●UPDRS-III 
●UPDRS - IV 
items 32-33 
●LFADLDS 
Stocchi et al 
(2009-2010) 
Australia, 
Canada, 
Finland, 
France, 
Germany, Italy, 
Japan, Spain 
[109] 
●Phase II 
Multicenter, 
randomized, 
double blind, 
parallel-group, 
placebo-
controlled 
(randomisation 
ratio 1:1:1:12:3) 
197 
subjects 
with 
moderate to 
severe LID 
●AFQ056 (n=133) 
Fixed-dose 
10mg bid 
25 mg bid 
50 mg bid 
75mg bid 
100mg bid  
/ 12 weeks 
Placebo (n=64) 
●mAIMS ●PDYS-26 
●CGIC 
●PGIC 
●UPDRS - IV 
items 32-33 
●UPDRS-III 
 
Kumar et al 
(2012) 
United States 
[110] 
●Phase II 
Multicenter, 
randomized, 
double blind, 
parallel-group, 
placebo-
controlled 
(randomisation 
ratio 1:1) 
14 subjects 
with 
moderate to 
severe LID 
●AFQ056 (n=7) 
dose-titration: 
25 to 100 mg bid / 6 
weeks 
Placebo (n=7) 
●LOCF in 
total OFF 
time 
●LOCF in on 
time with 
dyskinesia 
●UPDRS-III 
●mAIMS 
●UDysRS 
●CGIC 
●PGIC 
PD: Parkinson’s disease; LID: L-DOPA-induced dyskinesia; bid: twice a day; LFADLDS: Lang-Fahn 
Activities of Daily Living Dyskinesia Scale; UPDRS III: Unified Parkinson’s Disease Rating Scale-part III; 
mAIMS: modified Abnormal Involuntary Movements Scale: UPDRS IV: Unified Parkinson’s disease Rating 
Scale-part IV; LOCF: change from baseline to the last-observation-carried-forward; PDYS-26 Parkinson’s 
disease dyskinesia scale; CGIC: clinician-rated global impression of change; PGIC: patient-rated global 
impression of change; UDysRS Unified Dyskinesia Rating Scale. 
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Table 2.  Ongoing clinical trials testing drugs acting on mGlu5 receptor registred with 
www.ClinicalTrials.gov (on October 19, 2012). 
 
ID Sponsor Status 
Design/ 
Clinical trial 
phase 
Experimental drug, 
dose and duration 
 
Control 
Size 
(n) 
Condition 
PD 
NCT01385592 Novartis 
ANR 
 
DB RCT 
Phase II 
 
AFQ056  
100 mg  
12 weeks 
 
Placebo 63 
PD with 
moderate to 
severe LID 
NCT01491529 Novartis 
R 
(ESCD 
April 
2013) 
DB RCT 
Phase II 
 
AFQ056 
dose-titration: 
-150 mg bid 
- 200 mg bid  
2 and 4 weeks 
  
Placebo 140 
PD with 
severe LID 
NCT01173731 Novartis 
 
EI 
(ESCD 
Decemb
er 2014) 
 
OL, SG 
NRCT 
Phase II 
 
AFQ056 
NR dose 
3.5 years 
 
_ 119 PD with LID 
NCT01491932 Novartis 
R 
(ESCD 
October 
2015) 
OL, SG 
NRCT 
Phase II 
 
AFQ056  
dose-titration bid or 
the highest tolerated 
3 years 
 
_ 142 PD with LID 
ID: ClinicalTrials.gov Identifier; Size (n): Estimated enrolment of the number of patients; PD: Parkinson’s disease;  
Status: C (Completed) the study has been completed; R (Recruiting) the study is currently recruiting participants; 
ANR (Active, no Recruiting) the study is ongoing, but not recruiting participants; EI (enrolling by invitation) the 
study is enrolling participants by invitation only. ESCD: Estimated study completion data; DB: Double blind 
masking; OL: Open label masking; SG: Single group; RCT: randomised clinical trial; NRCT: non-randomised 
clinical trial; bid: twice a day; LID: L-DOPA-induced dyskinesia; NR: not reported. 
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Table 3. Baseline demographic and background characteristics of subjects. 
 Berg et al. 
(2007-2008) 
Berg et al. 
(2009) 
Stocchi et al. 
(2009-2010) 
Kumar et al. 
(2012) 
Number of subjects (%) 
   completed 
   discontinued 
       - adverse events 
       - death 
       - protocol deviation 
       - withdrew consent 
       - unsatisfactory           
therapeutic effect 
31 (100%) 
   30 (96.8%) 
   1 (3.2%) 
       - 1 (3.2%) 
       - 0 
       - 0 
       - 0 
       - 0 
 
28 (100%) 
   26 (92.8%) 
   2 (7.2%) 
      - 2 (7.2%) 
      - 0 
      - 0 
      - 0 
      - 0 
197 (100%) 
   145 (73.6%) 
   52 (26.4%) 
      - 25 (12.8%) 
      - 1 (0.5%) 
      - 6 (3.0%) 
      - 4 (2.0%) 
      - 16 (8.1%) 
     
14 (100%) 
   12 (85.7%) 
   2 (14.3%) 
      - 2 (14.3%) 
      - 0 
      - 0 
      - 0 
      - 0 
Age (years) 
Mean (SD) / Median (range) 
61.1 (10.3) / 63 (33-77) 65.8 (6.9) / 66 (52-79) 65.1 (8.7) / 66 (33-80) 61.4 (7.3) / 61.5 (46-74) 
Gender 
Male n (%) / Female n (%) 
 
16 (51.6) / 15 (48.4) 
 
17 (60.7) / 11 (39.3) 
 
105 (53.3) / 92 (46.7) 
 
6 (43) / 8 (57) 
Race n (%) 
Caucasian/Black/Asian/Other 
 
31 (100)/ 0/ 0/ 0 
 
NR 
 
158 (80.2) / 0 / 32 (16.2) / 7 
(3.6) 
 
14 (100) / 0 / 0 / 0 
Weight (kg) 
Mean (SD) / Median (range) 
70.7 (11) / 70.00 (47.3-97.5) 70.9 (13.7) / NR NR 77.3 (17.7) /  73.9 (44.4-104) 
BMI (Kg/m
2
) 
Mean (SD) / Median (range) 
NR NR 24.3 (4.1) / 24 (16-40.9) 23.4 (4.4) / 26,8 (18.7-34.1) 
Height (cm) 
Mean (SD) / Median (range) 
171.3 (8.2) / 170.0 (159-187) NR 165 (10.2) / 166 (138-189) 170.6 (11.9) / 171(154-190) 
Current Smoker 
Yes n (%) / No n (%) 
 
0 / 31 (100) 
 
0 / 28 (100) 
 
12 (6.1) / 185 (93.9) 
 
0 / 14 (100) 
Dyskinesia prior to 
randomization (months) 
> 3 > 3 > 3 > 3 
L-dopa treatment  
   Number of patients (%) 
   Time prior to 
randomization 
       - stable dose 
 
31 (100) 
   > 3 years 
       - > 1 month 
 
28 (100) 
   > 3 years 
      - > 1 month 
 
197 (100) 
   > 3 years 
      - > 4 months 
 
14 (100) 
   > 3 years 
      - NR  
Concomitant medication 
 
Pramipexole; Cabergoline; 
Ropinirole 
NR NR Carbidopa/L-DOPA 
NR: No reported 
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Table 4.  Efficacy Results: Mean change from baseline to day 16 on primary and 
secondary outcomes. 
Berg et al  
(2007-2008) 
Berg et al. 
(2009) 
Scale 
AFQ056 Placebo 
Difference 
(90% CI) 
AFQ056 Placebo 
Difference 
(90% CI) 
 
LFADLDS 
Day 16 
 
-4.60 -1.57 
-3.02  
(-5.12, -0.93)
* -3.84 -2.30 
-1.54  
(-3.69, -0.61) 
 
mAIMS 
Day 16 
 
-6.93 -1.63 
-5.31  
(-7.15, -3.46)
* -9.75 -4.84 
-4.91 
(-8.61, -
1.22)
* 
 
UPDRS-III 
Day 16 
 
-2.00 -4.25 
2.24  
(-1.65, - 6.14) 
-6.09 -2.79 
-3.30  
(-8.39, - 
1.79) 
UPDRS-IV 
Day 16 
-1.99 -0.82 
-1.16 
(-1.92, -0.41)
* -2.56 -0.98 
 
-1.58 
(-2.32, -
0.84)
* 
 
 
LFADLDS: Lang-Fahn Activities of Daily Living Dyskinesia Scale; mAIMS: modified 
Abnormal Involuntary; UPDRS III: Unified Parkinson’s disease Rating Scale-part III, 
Movements Scale; UPDRS IV: Unified Parkinson’s disease Rating Scale-part IV (items 32-
33). 
* 
P-value <0.05 when compared with placebo. 
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Table 5.  Efficacy Results: Mean change from baseline to week 12 on primary 
outcome.  
Stocchi et al  
 
 mAIMS 
baseline 
 
Mean (SD) 
mAIMS 
week 12 
 
Mean (SD) 
Adjusted 
change from 
baseline 
Mean (SD) 
Difference 
 
(95% CI) 
Pair wise 
comparisons 
 
p-value
b 
 
Placebo 13.4 (4.71) 10.4 (5.35) -2.9 (0.61) 
 
 
 
AFQ056 
20 mg daily 
14.5 (4.64) 11.3 (5.73) -2.7 (0.99) 0.2 (-2.7, 3.2) 0.743 
AFQ056 
50 mg daily 
12.9 (5.03) 7.6 (6.57) -5.5 (0.99) 
-2.6 (-5.5, 
0.4) 
0.046 
AFQ056 
100 mg daily 
13.5 (5.29) 9.8 (5.90) -3.6 (0.99) 
-0.6 (-3.6, 
2.3) 
0.571 
AFQ056 
150 mg daily 
13.9 (5.08) 10.8 (4.50) -2.8 (0.99) 0.1 (-2.8, 3.1) 0.743 
AFQ056 
200 mg daily 
13.2 (4.999 7.5 (5.00) -5.7 (0.75) 
-2.8 (-5.2, -
0.4) 
0.007 
Overall F-test 
p-value
a
 
 
    0.015 
mAIMS: modified Abnormal Involuntary Movement Scale. A negative change from baseline 
indicates improvement. An analysis of covariance (ANCOVA) model was used with baseline 
value as a covariate and treatment and country as factors. 
a 
The overall F-test tests if at least one dose differs from placebo. 
b 
Comparison of each dose group with placebo were made at the one-side error rate of 2.5%.   
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Table 6.  Most frequent adverse events possible or probably related to study-drug 
reported in subjects in either treatment group, by system organ class and 
preferred term (Safety Population) 
MedDRA System Organ Class/Preferred term 
AFQ056 (N=237)  
n (%) 
Placebo (N=100)  
n (%) 
Cardiac disorders   
Tachycardia 4 (1.7) 0 (-) 
Eye disorder   
Vision blurred/disturbed/impaired 6 (2.5) 0 (-) 
Gastrointestinal disorders   
Diarrhoea 7 (3.0) 3 (3.0) 
Nausea 9 (3.8) 8 (8.0) 
Vomiting 2 (0.8) 0 (-) 
Constipation 1 (0.4) 2 (2.0) 
Dry mouth  1 (0.4) 3 (3.0) 
Toothache  0 (-) 2 (2.0) 
General disorders and administration site conditions   
Fatigue 9 (3.8) 4 (4.0) 
Agitation  2 (0.8) 1 (1.0) 
Asthenia  0 (-) 2 (2.0) 
Infections and infestations   
Nasopharyngitis  8 (3.4) 0 (-) 
Urinary tract infection 4 (1.7) 0 (-) 
Injury, poisoning and procedural complications   
Fall  5 (2.1) 1 (1.0) 
Skin injury  1 (0.4) 0 (-) 
Traumatic haematoma 1 (0.4) 0 (-) 
Investigations   
Blood pressure increased  2 (0.8) 1 (1.0) 
Musculoskeletal and connective tissue disorders   
Pain in extremity 6 (2.5) 0 (-) 
Arthralgia 3 (1.3) 0 (-) 
Torticollis 1 (0.4) 0 (-) 
Rhabdomyolysis 1 (0.4) 0 (-) 
Nervous systems disorders   
Dizziness  36 (15.2) 5 (5.0) 
Dyskinesia 17 (7.2) 18 (18.0) 
Headache 6 (2.5) 3 (3.0) 
Parkinson’s disease 
* 
2 (0.8) 2 (2.0) 
Hyperkinesia 1 (0.4) 1 (1.0) 
Psychiatric disorders   
Hallucination 9 (3.8) 1 (1.0) 
Confusional state 8 (3.4) 0 (-) 
Insomnia  8 (3.4) 1 (1.0) 
Illusion 6 (2.5) 4 (4.0) 
Nervousness  4 (1.7) 0 (-) 
Psychotic disorder 3 (1.3) 0 (-) 
Euphoric mood 4 (1.7) 0 (-) 
Restlessness 1 (0.4) 0 (-) 
Reproductive system and breast disorders   
Priapism  2 (0.8) 0 (-) 
Skin and subcutaneous tissue disorders   
Skin burning sensation  2 (0.9) 0 (-) 
* 
Aggravation of symptoms. 
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